Bevacizumab-induced hypertension: Clinical presentation and molecular understanding
M Li, DL Kroetz - Pharmacology & therapeutics, 2018 - Elsevier
Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor
indicated as an adjunct to chemotherapy for the treatment of several types of cancer …
indicated as an adjunct to chemotherapy for the treatment of several types of cancer …
Bevacizumab-induced hypertension: pathogenesis and management
KN Syrigos, E Karapanagiotou, P Boura, C Manegold… - BioDrugs, 2011 - Springer
Bevacizumab, a recombinant humanized monoclonal antibody targeting the vascular
endothelial growth factor (VEGF), has been approved in the US as first-and second-line …
endothelial growth factor (VEGF), has been approved in the US as first-and second-line …
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies
HI Hurwitz, PS Douglas, JP Middleton… - The …, 2013 - academic.oup.com
Background. Hypertension is associated with antivascular endothelial growth factor
treatment, but the clinical implications of hypertension are uncertain. To assess the …
treatment, but the clinical implications of hypertension are uncertain. To assess the …
An observational study of bevacizumab‐induced hypertension as a clinical biomarker of antitumor activity
O Mir, R Coriat, L Cabanes, S Ropert… - The …, 2011 - academic.oup.com
Background. Hypertension is a common toxicity of bevacizumab, but the frequency of
assessment of blood pressure and standardized grading remain to be defined. This study …
assessment of blood pressure and standardized grading remain to be defined. This study …
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis
V Ranpura, B Pulipati, D Chu, X Zhu… - American journal of …, 2010 - academic.oup.com
Background Hypertension is associated with the use of bevacizumab, an angiogenesis
inhibitor widely used in cancer therapy. Currently, the risk of severe hypertension associated …
inhibitor widely used in cancer therapy. Currently, the risk of severe hypertension associated …
Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
MM An, Z Zou, H Shen, P Liu, ML Chen, YB Cao… - European journal of …, 2010 - Springer
Purpose Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial
growth factor. The aim of this study was to gain a better understanding of the overall …
growth factor. The aim of this study was to gain a better understanding of the overall …
[HTML][HTML] Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
[引用][C] Angiogenesis inhibitors and hypertension: an emerging issue
DA Sica - Journal of Clinical Oncology, 2006 - ascopubs.org
Any of a number of therapeutic agents or chemical substances can induce transient or more
long-lasting forms of hypertension. Drugs that cause hypertension do so by either …
long-lasting forms of hypertension. Drugs that cause hypertension do so by either …
Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab
A Pande, J Lombardo, E Spangenthal… - Anticancer …, 2007 - ar.iiarjournals.org
Background: Hypertension (HT) is a common complication of anti-angiogenic therapy. Its
incidence, treatment and complications are undefined. Patients and Methods: Retrospective …
incidence, treatment and complications are undefined. Patients and Methods: Retrospective …
Treatment of bevacizumab-induced hypertension by amlodipine
O Mir, R Coriat, S Ropert, L Cabanes, B Blanchet… - Investigational new …, 2012 - Springer
Background Hypertension is a common toxicity of anti-VEGF agents, but its optimal
treatment remains to define. This study aimed to describe the efficacy and tolerability of …
treatment remains to define. This study aimed to describe the efficacy and tolerability of …